Doctors treating advanced prostate cancer start patients on hormone therapy plus a drug called an androgen receptor pathway inhibitor, or ARPI. These drugs work well for most men, but doctors must wait six months to check if the PSA blood level drops very low, to 0.2 nanograms per milliliter or less. This low PSA strongly […]
The ANDROMEDA trial, a first-in-human Phase 1/2 study, is evaluating AZD9750, a novel androgen receptor (AR) PROTAC, in men with metastatic castration-resistant prostate cancer (mCRPC). PROTACs represent a paradigm shift in targeted therapy: unlike traditional AR inhibitors that merely block the receptor’s activity, AZD9750 recruits cellular machinery to completely degrade the AR protein, potentially overcoming […]
Note: This article treats GSK5471713 as an androgen receptor (AR) degrader based on GSK’s official clinical trial registry classification and inclusion/exclusion criteria. While confident in the AR degrader designation from the sponsor’s documentation, the specific degradation mechanism (PROTAC, SARD, or other platform) remains undisclosed in publicly available sources at the moment. GSK5471713 is an investigational […]
Researchers at Tsinghua University in China have created DrugCLIP, an AI system that finds potential new medicines millions of times faster than old methods. Traditional drug discovery uses slow computer simulations to check if a small molecule fits into a protein’s binding pocket, the spot where drugs attach to block or change a protein’s action […]
Researchers at the University of British Columbia have achieved a major advance in stem cell engineering by developing a reliable method to produce helper T cells from stem cells in a controlled lab environment. This breakthrough, detailed in the journal Cell Stem Cell, tackles a persistent obstacle in cell therapy production, making treatments more affordable […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Here I am again! I think research is still a bit on holiday in terms of the number of studies, but the quality of the trials expected to start in 2026 looks very high. Let’s take a look at […]
Copanlisib combined with rucaparib demonstrates tolerability and early signals of activity in metastatic castration-resistant prostate cancer (mCRPC), according to results from the BrUOG360 phase Ib/II trial published in late 2025. Metastatic castration-resistant prostate cancer with homologous recombination deficiency (HRD) responds to PARP inhibitors like rucaparib, but many patients develop resistance through alternative DNA repair pathways. […]
Sapu-003, a nanoparticle-formulated version of everolimus delivered via a new platform (Deciparticle) has received approval for first-in-human Phase 1 testing in breast cancer patients, representing a major advance in intravenous oncology drug delivery. Unlike the standard oral everolimus tablet, which achieves only 10-20% bioavailability due to extensive first-pass metabolism and gastrointestinal degradation, the Deciparticle platform […]
ADI-212 is a new type of immune cell therapy made from gamma delta T cells, the kind of immune cells that naturally go after tumors. These cells are specially engineered to attack PSMA-positive metastatic castration-resistant prostate cancer. The therapy has two smart upgrades. First, it carries a special version of IL-12, a powerful immune signal, […]
PSMA-targeted radioligand therapy (RLT) has transformed treatment for end-stage prostate cancer, offering strong tumor control in patients who have exhausted other options. However, these therapies frequently cause severe salivary gland damage, leading to debilitating dry mouth that often forces patients to stop treatment early. To overcome this, researchers at Case Western Reserve University developed PSMA-1-DOTA, […]